Genetic variants of microsomal triglyceride transfer protein (MTTP) are associated with metabolic syndrome in schizophrenic patients treated with atypical antipsychotics

• Published in: Journal of clinical psychopharmacology Vol. 33; no. 3; p. 313
• Main Authors: Liou, Ying-Jay, Tsai, Shih-Jen, Wang, Ying-Chieh, Bai, Ya Mei, Hong, Chen-Jee
• Format: Journal Article
• Language: English
• Published: United States 01.06.2013
• Subjects: Adult; Alleles; Antipsychotic Agents - adverse effects; Antipsychotic Agents - therapeutic use; Carrier Proteins - genetics; Cross-Sectional Studies; Female; Genotype; Humans; Male; Metabolic Syndrome - epidemiology; Metabolic Syndrome - etiology; Metabolic Syndrome - genetics; Middle Aged; Polymorphism, Single Nucleotide; Risk Factors; Schizophrenia - drug therapy; Time Factors
• ISSN: 1533-712X
• DOI: 10.1097/JCP.0b013e31828bf288

Promoter polymorphisms in microsomal triglyceride transfer protein (MTTP) have been associated with the various traits of metabolic syndrome (MetS) in the general population. This study investigated whether the common variants in MTTP genes were associated with MetS in schizophrenic patients treated with atypical antipsychotics. The study included 456 hospitalized patients diagnosed with schizophrenia, who had been treated with clozapine (n = 171), olanzapine (n = 91), or risperidone (n = 194) for at least 3 months. Patients were genotyped for the 10 MTTP single-nucleotide polymorphisms. The prevalence of MetS among all subjects was 22.8%. In single-marker-based analysis, the MTTP rs1800591 (-493G>T) T-allele carriers were at double the risk for MetS relative to G/G homozygotes. In contrast, the T-allele homozygotes had considerably lower fasting high-density lipoprotein levels than that in the heterozygotes or G-allele homozygotes. Our findings extend and add new information to the existing data regarding the association between MTTP genetic variants and MetS regulation during long-term atypical antipsychotic treatment. The MTTP rs1800591 T allele could be a risk factor for MetS in patients under atypical antipsychotic medication.